Biologics as a first-line systemic therapy are associated with better clinical outcomes and lower risks for chronic comorbidities in patients with moderate-to-severe psoriasis.
Use of biologics increases the risk for treatment escalation to systemic therapies among patients with inflammatory acne.
Research on best options is sparse, but biologics can still be helpful for HIV-positive patients with psoriasis.
Interleukin-23 inhibitors, prior treatment history, and Psoriasis Area and Severity Index scores may be predictive of time to disease relapse among patients with psoriasis who achieved clinical ...
Less than 15% of adults with uncontrolled asthma eligible for biologic therapy reported current biologic use, according to survey data presented at the American Academy of Allergy, Asthma & Immunology ...
Understand how step therapy affects psoriasis treatment. Learn about the ‘fail first’ process, the impact of treatment delays ...
Antibiotic exposure in psoriasis patients is linked to increased biologic therapy discontinuation, with risk rising with multiple courses, suggesting gut microbiota alterations may play a role. The ...
Two posters demonstrated povorcitinib's durable 54-week efficacy and a favorable safety profile in moderate to severe HS, including patients previously on anti-TNF therapy. HS, a chronic, recurrent ...
Please provide your email address to receive an email when new articles are posted on . Biologic therapies are underutilized in non-white populations. By identifying barriers to specific biologic ...
Hosted on MSN
Biologic therapy significantly improves pregnancy outcomes in women with antiphospholipid syndrome
A clinical trial co-led by the Hospital for Special Surgery (HSS) has found that blocking inflammation with the drug certolizumab significantly reduces the risk of serious adverse pregnancy outcomes ...
Biologic Therapies has announced it has received FDA clearance for its new bone marrow aspiration catheter, according to a news release. The Bio-MAC bone marrow aspiration catheter is designed to ...
Data showed 50% or more of patients reporting >50% improvement in key pain and function scales No adverse events related to dose-limiting ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results